KOD

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Retrieved on: 
Tuesday, January 30, 2024

PALO ALTO, Calif., Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting.

Key Points: 
  • PALO ALTO, Calif., Jan. 30, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting.
  • KSI-501ABC is the second product candidate built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform.
  • "We look forward to sharing for the first time the results of our Phase 1 study of KSI-501ABC, our anti-IL-6 antibody and VEGF-trap bispecific therapeutic candidate in its antibody biopolymer conjugate form.
  • We believe these early results support further clinical development of the KSI-501 program," said Dr. J. Pablo Velazquez-Martin, MD., Senior Vice President of Clinical Research and Development.

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024

PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Key Points: 
  • PALO ALTO, Calif., Jan. 4, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
  • A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.

Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society

Retrieved on: 
Wednesday, October 11, 2023

PALO ALTO, Calif., Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration (AMD), a first-time presentation of the Year 1 head-to-head results from the Phase 3 BEACON study in retinal vein occlusion (RVO), and the primary results and new analyses from the Phase 3 GLEAM and GLIMMER studies in diabetic macular edema (DME), will be shared at the 56th Annual Scientific Meeting of The Retina Society, being held from Oct 11 – 14 in New York, United States.

Key Points: 
  • PALO ALTO, Calif., Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration (AMD), a first-time presentation of the Year 1 head-to-head results from the Phase 3 BEACON study in retinal vein occlusion (RVO), and the primary results and new analyses from the Phase 3 GLEAM and GLIMMER studies in diabetic macular edema (DME), will be shared at the 56th Annual Scientific Meeting of The Retina Society, being held from Oct 11 – 14 in New York, United States.
  • "At the Retina Society meeting, data will be presented across four pivotal trials for tarcocimab and will include the results of recent investigations on the higher cataract incidence in patients with DME and the implications of our ongoing findings on the development of our ABC Platform derived medicines," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.
  • The following will be presented at the meeting by our clinical investigators:
    Title: Tarcocimab tedromer (KSI-301) 5 mg for the treatment of wAMD: One-year primary efficacy,durability, and safety outcomes of the Phase 3 DAYLIGHT Study
    Title: Tarcocimab tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for Diabetic Macular Edema: Primary Endpoint Efficacy and Safety Outcomes of the GLEAM and GLIMMER Phase 3 Pivotal Studies
    Title: Tarcocimab tedromer (KSI-301) 5 mg for the treatment of RVO: One-year primary efficacy, durability, and safety outcomes of the Phase 3 BEACON Study
    Kodiak plans to post the presentation slides on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ at the beginning of each presentation.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Kodiak Sciences Inc. – KOD

Retrieved on: 
Wednesday, August 2, 2023

NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD).

Key Points: 
  • NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Kodiak and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Investigation of Kodiak Sciences Inc. (KOD) Announced by Holzer & Holzer, LLC

Retrieved on: 
Thursday, July 27, 2023

ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD) complied with federal securities laws.

Key Points: 
  • ATLANTA, July 27, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD) complied with federal securities laws.
  • If you purchased Kodiak stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq.
  • Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.
  • Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.

Kodiak Sciences to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 30, 2023

PALO ALTO, Calif., May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences:

Key Points: 
  • PALO ALTO, Calif., May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the following upcoming investor conferences:
    Jefferies Healthcare Conference, June 7, 2023, 1:30 PM ET (10:30 AM PT), New York, New York
    Goldman Sachs 44th Annual Global Healthcare Conference, June 14, 2023, 7:40 PM ET (4:40 PM PT), Dana Point, California
    A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.

Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting

Retrieved on: 
Friday, April 21, 2023

"We look forward to sharing data across our pipeline of investigational medicines at this year's ARVO Annual Meeting," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.

Key Points: 
  • "We look forward to sharing data across our pipeline of investigational medicines at this year's ARVO Annual Meeting," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.
  • "Our efforts encompass Phase 3 clinical studies with our lead tarcocimab tedromer, a Phase 1 clinical study with our new bispecific KSI-501, and earlier discovery efforts.
  • We believe the data being presented will demonstrate the robust retina-focused research and development engine at Kodiak.
  • We remain committed to our mission of bringing new science to the prevention and treatment of high prevalence retinal diseases."

Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting

Retrieved on: 
Thursday, February 9, 2023

We anticipate four Phase 3 clinical study readouts later this year, in approximately 3Q2023.

Key Points: 
  • We anticipate four Phase 3 clinical study readouts later this year, in approximately 3Q2023.
  • "We are also pleased to have successfully opened the IND for KSI-501, our second product candidate built from the ABC platform.
  • KSI-501 is a potential first-in-class bispecific ABC that is designed to inhibit two powerful pathophysiologic mechanisms in retinal disease, VEGF and IL-6.
  • Kodiak plans to post the presentation slides on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ at the beginning of the presentation.

Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 4, 2023

Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases.

Key Points: 
  • Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases.
  • Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development.
  • KSI-501 is our dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases.
  • Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference

Retrieved on: 
Wednesday, November 16, 2022

PALO ALTO, Calif., Nov. 16, 2022 /PRNewswire/ --Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022, at 9:10am Pacific Time (12:10pm Eastern Time).

Key Points: 
  • PALO ALTO, Calif., Nov. 16, 2022 /PRNewswire/ --Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022, at 9:10am Pacific Time (12:10pm Eastern Time).
  • Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases.
  • Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development.
  • Kodiak, Kodiak Sciences, ABC, ABC Platform and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.